Do antidepressants regulate how cortisol affects the brain?

Psychoneuroendocrinology

Volumn 29, Issue 4, 2004, Pages 423-447

  Pariante, Carmine M ^a   Thomas, Sarah A ^a   Lovestone, Simon ^a   Makoff, Andrew ^a   Kerwin, Robert W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antidepressant; Glucocorticoid receptor; Hypothalamic pituitary adrenal axis; Mineralocorticoid receptor; Multidrug resistance; p Glycoprotein

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DEXAMETHASONE; FLUOXETINE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; OXAPROTILINE; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE; VENLAFAXINE; ZIMELDINE;

BLOOD BRAIN BARRIER; BRAIN CELL; CLINICAL TRIAL; DRUG EFFECT; FIBROBLAST; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ISOTOPE LABELING; MAJOR DEPRESSION; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 1642553626     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2003.10.009     Document Type: Article

References (126)

1. Bergman A.M., Pinedo H.M., Peters G.J. Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells. Eur. J. Pharmacol. 416:2001;19-24.
2. Bjartmar L., Johansson I.M., Marcusson J., Ross S.B., Seckl J.R., Olsson T. Selective effects on NGFI-A, MR, GR and NGFI-B hippocampal mRNA expression after chronic treatment with different subclasses of antidepressants in the rat. Psychopharmacology (Berl). 151:2000;7-12.
3. Bossuyt X., Muller M., Hagenbuch B., Meier P.J. Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J. Pharmacol. Exp. Ther. 276:1996;891-896.
4. Bourgeois S., Gruol D.J., Newby R.F., Rajah F.M. Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol. Endocrinol. 7:1993;840-851.
5. Bouwer C., Claassen J., Dinan T.G., Nemeroff C.B. Prednisone augmentation in treatment-resistant depression with fatigue and hypocortisolaemia: a case series. Depress. Anxiety. 12:2000;44-50.
6. Brady L.S., Whitfield H.J. Jr., Fox R.J., Gold P.W., Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J. Clin. Invest. 87:1991;831-837.
7. Brady L.S., Gold P.W., Herkenham M., Lynn A.B., Whitfield H.J. Jr. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin- releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res. 572:1992;117-125.
8. Brooksbank B.W., Brammall M.A., Shaw D.M. Estimation of cortisol, cortisone and corticosterone in cerebral cortex, hypothalamus and other regions of the human brain after natural death and after death by suicide. Steroids Lipids Res. 4:1973;162-183.
9. Budziszewska B., Siwanowicz J., Przegalinski E. The effect of chronic treatment with antidepressant drugs on the corticosteroid receptor levels in the rat hippocampus. Pol. J. Pharmacol. 46:1994;147-152.
10. Budziszewska B., Jaworska-Feil L., Kajta M., Lason W. Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism. Br. J. Pharmacol. 130:2000;1385-1393.
11. Castaing M., Brouant P., Loiseau A., Santelli-Rouvier C., Santelli M., Alibert-Franco S., Mahamoud A., Barbe J. Membrane permeation by multidrug-resistance-modulators and non-modulators: effects of hydrophobicity and electric charge. J. Pharm. Pharmacol. 52:2000;289-296.
12. Chen J., Rasenick M.M. Chronic treatment of C6 glioma cells with antidepressant drugs increases functional coupling between a G protein (Gs) and adenylyl cyclase. J. Neurochem. 64:1995;724-732.
13. Cotter D., Pariante C.M. Stress and the progression of the developmental hypothesis of schizophrenia. Br. J. Psychiatry. 181:2002;363-365.
14. Danielsen M., Northrop J.P., Ringold G.M. The mouse glucocorticoid receptor: mapping of functional domains by cloning, sequencing and expression of wild-type and mutant receptor proteins. EMBO J. 5:1986;2513-2522.
15. de Kloet E.R., Vreugdenhil E., Oitzl M.S., Joels M. Brain corticosteroid receptor balance in health and disease. Endocr. Rev. 19:1998;269-301.
16. DeBattista C., Posener J.A., Kalehzan B.M., Schatzberg A.F. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. Am. J. Psychiatry. 157:2000;1334-1337.
17. Delbende C., Contesse V., Mocaer E., Kamoun A., Vaudry H. The novel antidepressant, tianeptine, reduces stress-evoked stimulation of the hypothalamo-pituitary-adrenal axis. Eur. J. Pharmacol. 202:1991;391-396.
18. Dinan T.G., Lavelle E., Cooney J., Burnett F., Scott L., Dash A., Thakore J., Berti C. Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr. Scand. 95:1997;58-61.
19. Duman R.S., Nakagawa S., Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology. 25:2001;836-844.
20. Ebrecht M., Buske-Kirschbaum A., Hellhammer D., Kern S., Rohleder N., Walker B., Kirschbaum C. Tissue specificity of glucocorticoid sensitivity in healthy adults. J. Clin. Endocrinol. Metab. 85:2000;3733-3739.
21. Eiring A., Sulser F. Increased synaptic availability of norepinephrine following desipramine is not essential for increases in GR mRNA. Short communication. J. Neural Transm. 104:1997;1255-1258.
22. Ekins S., Kim R.B., Leake B.F., Dantzig A.H., Schuetz E.G., Lan L.B., Yasuda K., Shepard R.L., Winter M.A., Schuetz J.D., Wikel J.H., Wrighton S.A. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharmacol. 61:2002;974-981.
23. Felix R.A., Barrand M.A. P-glycoprotein expression in rat brain endothelial cells: evidence for regulation by transient oxidative stress. J. Neurochem. 80:2002;64-72.
24. Ferte J. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur. J. Biochem. 267:2000;277-294.
25. Ford J.M. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur. J. Cancer. 32A:1996;991-1001.
26. Gibbs J.E., Thomas S.A. The distribution of the anti-HIV drug, 2′3′-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J. Neurochem. 80:2002;392-404.
27. Gibbs J., Jayabalan P., Thomas S.A. Mechanisms by which 2′3′-dideoxyinosine (ddI) crosses the guinea-pig CNS barriers; relevance to HIV therapy. J. Neurochem. 84:2003;725-734.
28. Goodsell D.S. The molecular perspective: the multidrug transporter. Stem Cells. 17:1999;377-378.
29. Guiochon-Mantel A., Delabre K., Lescop P., Milgrom E. The Ernst Schering Poster Award. Intracellular traffic of steroid hormone receptors. J. Steroid Biochem. Mol. Biol. 56:1996;3-9.
30. Heiske A., Jesberg J., Krieg J.C., Vedder H. Differential effects of antidepressants on glucocorticoid receptors in human primary blood cells and human monocytic u-937 cells. Neuropsychopharmacology. 28:2003;807-817.
31. Herr, A.S., Tsolakidou, A.F., Yassouridis, A., Holsboer, F., Rein, T., 2003. Antidepressants differentially influence the transcriptional activity of the glucocorticoid receptor in vitro. Neuroendocrinology 78, 12-22.
32. Herr A.S., Wochnik G.M., Rosenhagen M.C., Holsboer F., Rein T. Rifampicin is not an activator of glucocorticoid receptor. Mol. Pharmacol. 57:2000;732-737.
33. Hery M., Semont A., Fache M.P., Faudon M., Hery F. The effects of serotonin on glucocorticoid receptor binding in rat raphe nuclei and hippocampal cells in culture. J. Neurochem. 74:2000;406-413.
34. Heuser I., Yassouridis A., Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J. Psychiatr. Res. 28:1994;341-356.
35. Heuser I.J., Schweiger U., Gotthardt U., Schmider J., Lammers C.H., Dettling M., Yassouridis A., Holsboer F. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am. J. Psychiatry. 153:1996;93-99.
36. Hirrlinger J., Konig J., Dringen R. Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. J. Neurochem. 82:2002;716-719.
37. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 23:2000;477-501.
38. Htun H., Barsony J., Renyi I., Gould D.L., Hager G.L. Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera. Proc. Natl. Acad. Sci. USA. 93:1996;4845-4850.
39. Johansson I.M., Bjartmar L., Marcusson J., Ross S.B., Seckl J.R., Olsson T. Chronic amitriptyline treatment induces hippocampal NGFI-A, glucocorticoid receptor and mineralocorticoid receptor mRNA expression in rats. Mol. Brain Res. 62:1998;92-95.
40. Kalman B.A., Spencer R.L. Rapid corticosteroid-dependent regulation of mineralocorticoid receptor protein expression in rat brain. Endocrinology. 143:2002;4184-4195.
41. Karssen A.M., Meijer O.C., van der Sandt I., Lucassen P.J., de Lange E.C., de Boer A.G., de Kloet E.R. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology. 142:2001;2686-2694.
42. Karssen A.M., Meijer O.C., van der Sandt I., de Boer A.G., de Lange E.C., de Kloet E.R. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J. Endocrinol. 175:2002;251-260.
43. Keightley M.C., Fuller P.J. Anomalies in the endocrine axes of the guinea pig: relevance to human physiology and disease. Endocr. Rev. 17:1996;30-44.
44. Kitayama I., Janson A.M., Cintra A., Fuxe K., Agnati L.F., Ogren S.O., Harfstrand A., Eneroth P., Gustafsson J.A. Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain. Evidence for selective increases of glucocorticoid receptor immunoreactivity in the locus coeruleus and in 5-hydroxytryptamine nerve cell groups of the rostral ventromedial medulla. J. Neural Transm. 73:1988;191-203.
45. Kralli A., Yamamoto K.R. An FK506-sensitive transporter selectively decreases intracellular levels and potency of steroid hormones. J. Biol. Chem. 271:1996;17152-17156.
46. Kurowski C., Berthold F. Presence of classical multidrug resistance and P-glycoprotein expression in human neuroblastoma cells. Ann. Oncol. 9:1998;1009-1014.
47. Kwan P., Sills G.J., Butler E., Gant T.W., Meldrum B.S., Brodie M.J. Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure. Epilepsia. 43:2002;1318-1323.
48. Lackner C., Daufeldt S., Wildt L., Allera A. Glucocorticoid-recognizing and -effector sites in rat liver plasma membrane. Kinetics of corticosterone uptake by isolated membrane vesicles. III. Specificity and stereospecificity. J. Steroid Biochem. Mol. Biol. 64:1998;69-82.
49. Lai M., McCormick J.A., Chapman K.E., Kelly P.A.T., Seckl J.R., Yau J.L.W. Differential regulation of corticosteroid receptors by monoamine neurotransmitters and antidepressant drugs in primary hippocampal culture. Neuroscience. 118:2003;975-984.
50. Lee G., Dallas S., Hong M., Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53:2001;569-596.
51. Leslie E.M., Deeley R.G., Cole S.P. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology. 167:2001;3-23.
52. Linkowski P., Mendlewicz J., Kerkhofs M., Leclercq R., Golstein J., Brasseur M., Copinschi G., Van Cauter E. 24-Hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: effect of antidepressant treatment. J. Clin. Endocrinol. Metab. 65:1987;141-152.
53. Lopez J.F., Chalmers D.T., Little K.Y., Watson S.J. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry. 43:1998;547-573.
54. Marsaud V., Mercier-Bodard C., Fortin D., Le Bihan S., Renoir J.M. Dexamethasone and triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, rapamycin and their analogues, as well as by other P-glycoprotein ligands. J. Steroid Biochem. Mol. Biol. 66:1998;11-25.
55. Matsuoka Y., Okazaki M., Kitamura Y., Taniguchi T. Developmental expression of P-glycoprotein (multidrug resistance gene product) in the rat brain. J. Neurobiol. 39:1999;383-392.
56. McEwen B.S. The neurobiology of stress: from serendipity to clinical relevance. Brain Res. 886:2000;172-189.
57. McQuade R., Young A.H. Future therapeutic targets in mood disorders: the glucocorticoid receptor. Br. J. Psychiatry. 177:2000;390-395.
58. Medh R.D., Lay R.H., Schmidt T.J. Agonist-specific modulation of glucocorticoid receptor-mediated transcription by immunosuppressants. Mol. Cell Endocrinol. 138:1998;11-23.
59. Meijer O.C., de Lange E.C., Breimer D.D., de Boer A.G., Workel J.O., de Kloet E.R. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology. 139:1998;1789-1793.
60. Merry S., Hamilton T.G., Flanigan P., Freshney R.I., Kaye S.B. Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine. Eur. J. Cancer. 27:1991;31-34.
61. Miller A.H., Vogt G.J., Pearce B.D. The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function. Neuropsychopharmacology. 27:2002;939-948.
62. Montkowski A., Barden N., Wotjak C., Stec I., Ganster J., Meaney M., Engelmann M., Reul J.M., Landgraf R., Holsboer F. Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J. Neuroendocrinol. 7:1995;841-845.
63. Mulder H.S., Pinedo H.M., Timmer A.T., Rao B.R., Lankelma J. Multidrug resistance-modifying components in human plasma with potential clinical significance. J. Exp. Ther. Oncol. 1:1996;13-22.
64. Muller, M.B., Keck, M.E., Binder, E.B., Kresse, A.E., Hagemeyer, T.P., Landgraf, R., Holsboer, F., Uhr, M., 2003. ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary- adrenocortical system: implications for affective discorder. Neuropsychopharmacology 28, 1991-1999.
65. Nemeroff C.B. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol. Psychiatry. 1:1996;336-342.
66. Nestler E.J. Antidepressant treatments in the 21st century. Biol. Psychiatry. 44:1998;526-533.
67. Nishi M., Takenaka N., Morita N., Ito T., Ozawa H., Kawata M. Real-time imaging of glucocorticoid receptor dynamics in living neurons and glial cells in comparison with non-neural cells. Eur. J. Neurosci. 11:1999;1927-1936.
68. Nishi M., Ogawa H., Ito T., Matsuda K.I., Kawata M. Dynamic changes in subcellular localization of mineralocorticoid receptor in living cells: in comparison with glucocorticoid receptor using dual-color labeling with green fluorescent protein spectral variants. Mol. Endocrinol. 15:2001;1077-1092.
69. Okugawa G., Omori K., Suzukawa J., Fujiseki Y., Kinoshita T., Inagaki C. Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones. J. Neuroendocrinol. 11:1999;887-895.
70. Okuyama-Tamura, M., Mikuni, M., Kojima, I., 2003. Modulation of the human glucocorticoid receptor function by antidepressive compounds. Neurosci. Lett. 342, 206-210.
71. Orth D., Kovacs W. The adrenal cortex. Wilson J., Foster D., Kronenberg H., Larsen P. Williams Textbook of Endocrinology. ninth ed. 1998;517-664 W.B. Saunders Company, Philadelphia.
72. Owens M.J., Nemeroff C.B. The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba Found. Symp. 172:1993;296-308.
73. Pariante C.M. Depression, stress and the adrenal axis. J. Neuroendocrinol. 15:2003;811-812.
74. Pariante C.M., Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry. 49:2001;391-404.
75. Pariante C.M., Pearce B.D., Pisell T.L., Owens M.J., Miller A.H. Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol. Pharmacol. 52:1997;571-581.
76. Pariante C.M., Pearce B.D., Pisell T.L., Sanchez C.I., Po C., Su C., Miller A.H. The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology. 140:1999;4359-4366.
77. Pariante C.M., Makoff A., Lovestone S., Feroli S., Heyden A., Miller A.H., Kerwin R.W. Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br. J. Pharmacol. 134:2001a;1335-1343.
78. Pariante C.M., Pearce B.D., Pisell T.L., Su C., Miller A.H. The steroid receptor antagonists RU40555 and RU486 activate glucocorticoid receptor translocation and are not excreted by the steroid hormones transporter in L929 cells. J. Endocrinol. 169:2001b;309-320.
79. Pariante C.M., Papadopoulos A.S., Poon L., Checkley S.A., English J., Kerwin R.W., Lightman S. A novel prednisolone suppression test for the hypothalamic-pituitary-adrenal axis. Biol. Psychiatry. 51:2002;922-930.
80. Pariante C.M., Hye A., Williamson R., Makoff A., Lovestone S., Kerwin R.W. The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology. 28:2003a;1553-1561.
81. Pariante C.M., Kim R.B., Makoff A., Kerwin R.W. The antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br. J. Pharmacol. 139:2003b;1111-1118.
82. Peeters B.W., van der H.R., Gubbels D.G., Vanderheyden P.M. Effects of chronic antidepressant treatment on the hypothalamic-pituitary-adrenal axis of Wistar rats. Ann. N.Y. Acad. Sci. 746:1994;449-452.
83. Peiffer A., Veilleux S., Barden N. Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology. 16:1991;505-515.
84. Pepin M.C., Beaulieu S., Barden N. Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Mol. Brain Res. 6:1989;77-83.
85. Pepin M.C., Govindan M.V., Barden N. Increased glucocorticoid receptor gene promoter activity after antidepressant treatment. Mol. Pharmacol. 41:1992a;1016-1022.
86. Pepin M.C., Pothier F., Barden N. Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression. Mol. Pharmacol. 42:1992b;991-995.
87. Prima V., Depoix C., Masselot B., Formstecher P., Lefebvre P. Alteration of the glucocorticoid receptor subcellular localization by non steroidal compounds. J. Steroid Biochem. Mol. Biol. 72:2000;1-12.
88. Przegalinski E., Budziszewska B. The effect of long-term treatment with antidepressant drugs on the hippocampal mineralocorticoid and glucocorticoid receptors in rats. Neurosci. Lett. 161:1993;215-218.
89. Przegalinski E., Budziszewska B., Siwanowicz J., Jaworska L. The effect of repeated combined treatment with nifedipine and antidepressant drugs or electroconvulsive shock on the hippocampal corticosteroid receptors in rats. Neuropharmacology. 32:1993;1397-1400.
90. Rangarajan P.N., Umesono K., Evans R.M. Modulation of glucocorticoid receptor function by protein kinase A. Mol. Endocrinol. 6:1992;1451-1457.
91. Regina A., Koman A., Piciotti M., El Hafny B., Center M.S., Bergmann R., Couraud P.O., Roux F. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J. Neurochem. 71:1998;705-715.
92. Reul J.M., Stec I., Soder M., Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology. 133:1993;312-320.
93. Reul J.M., Labeur M.S., Grigoriadis D.E., De Souza E.B., Holsboer F. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology. 60:1994;509-519.
94. Reul J.M., Gesing A., Droste S., Stec I.S., Weber A., Bachmann C., Bilang-Bleuel A., Holsboer F., Linthorst A.C. The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. Eur. J. Pharmacol. 405:2000;235-249.
95. Ribeiro S.C., Tandon R., Grunhaus L., Greden J.F. The DST as a predictor of outcome in depression: a meta-analysis. Am. J. Psychiatry. 150:1993;1618-1629.
96. Rossby S.P., Nalepa I., Huang M., Perrin C., Burt A.M., Schmidt D.E., Gillespie D.D., Sulser F. Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant. Brain Res. 687:1995;79-82.
97. Sanchez E.R., Hu J.L., Zhong S., Shen P., Greene M.J., Housley P.R. Potentiation of glucocorticoid receptor-mediated gene expression by heat and chemical shock. Mol. Endocrinol. 8:1994;408-421.
98. Schafer W.R. How do antidepressants work? Prospects for genetic analysis of drug mechanisms. Cell. 98:1999;551-554.
99. Schinkel A.H. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 36:1999;179-194.
100. Schmidt T.J., Meyer A.S. Autoregulation of corticosteroid receptors. How, when, where, and why? Receptor. 4:1994;229-257.
101. Seckl J.R., Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology. 55:1992;621-626.
102. Semont A., Fache M., Hery F., Faudon M., Youssouf F., Hery M. Regulation of central corticosteroid receptors following short-term activation of serotonin transmission by 5-hydroxy-L-tryptophan or fluoxetine. J. Neuroendocrinol. 12:2000;736-744.
103. Shabbits J.A., Krishna R., Mayer L.D. Molecular and pharmacological strategies to overcome multidrug resistance. Expert. Rev. Anticancer Ther. 1:2001;585-594.
104. Sisodiya S.M., Lin W.R., Harding B.N., Squier M.V., Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain. 125:2002;22-31.
105. Szabo D., Szabo G. Jr., Ocsovszki I., Aszalos A., Molnar J. Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett. 139:1999;115-119.
106. Thomas S.A., Segal M.B. Saturation kinetics, specificity and NBMPR sensitivity of thymidine entry into the central nervous system. Brain Res. 760:1997;59-67.
107. Thomas S.A., Segal M.B. The transport of the anti-HIV drug, 2′,3′-didehydro-3′-deoxythymidine (D4T), across the blood-brain and blood-cerebrospinal fluid barriers. Br. J. Pharmacol. 125:1998;49-54.
108. Thomas S.A., Bye A., Segal M.B. Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid. J. Pharmacol. Exp. Ther. 298:2001;947-953.
109. Ueda K., Okamura N., Hirai M., Tanigawara Y., Saeki T., Kioka N., Komano T., Hori R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem. 267:1992;24248-24252.
110. Uhr M., Grauer M.T. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J. Psychiatr. Res. 37:2003;179-185.
111. Uhr M., Steckler T., Yassouridis A., Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology. 22:2000;380-387.
112. Uhr M., Holsboer F., Muller M.B. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J. Neuroendocrinol. 14:2002;753-759.
113. Varga A., Nugel H., Baehr R., Marx U., Hever A., Nacsa J., Ocsovszky I., Molnar J. Reversal of multidrug resistance by amitriptyline in vitro. Anticancer Res. 16:1996;209-211.
114. Vedder H., Bening-Abu-Shach U., Lanquillon S., Krieg J.C. Regulation of glucocorticoid receptor-mRNA in human blood cells by amitriptyline and dexamethasone. J. Psychiatr. Res. 33:1999;303-308.
115. Webster J.I., Carlstedt-Duke J. Involvement of multidrug resistance proteins (MDR) in the modulation of glucocorticoid response. J. Steroid Biochem. Mol. Biol. 82:2002;277-288.
116. Webster M.J., Knable M.B., O'Grady J., Orthmann J., Weickert C.S. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol. Psychiatry. 7:(985-94):2002;924.
117. Wodarz N., Rupprecht R., Kornhuber J., Schmitz B., Wild K., Riederer P. Cell-mediated immunity and its glucocorticoid-sensitivity after clinical recovery from severe major depressive disorder. J. Affect. Disord. 25:1992;31-38.
118. Wolf D.C., Horwitz S.B. P-glycoprotein transports corticosterone and is photoaffinity-labeled by the steroid. Int. J. Cancer. 52:1992;141-146.
119. Yang J., DeFranco D.B. Assessment of glucocorticoid receptor-heat shock protein 90 interactions in vivo during nucleocytoplasmic trafficking. Mol. Endocrinol. 10:1996;3-13.
120. Yau J.L., Olsson T., Morris R.G., Meaney M.J., Seckl J.R. Glucocorticoids, hippocampal corticosteroid receptor gene expression and antidepressant treatment: relationship with spatial learning in young and aged rats. Neuroscience. 66:1995;571-581.
121. Yau J.L., Noble J., Hibberd C., Seckl J.R. Short-term administration of fluoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus. Neurosci. Lett. 306:2001;161-164.
122. Yau J.L., Hibberd C., Noble J., Seckl J.R. The effect of chronic fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats. Mol. Brain Res. 106:2002;117-123.
123. Young E.A., Spencer R.L., McEwen B.S. Changes at multiple levels of the hypothalamo-pituitary adrenal axis following repeated electrically induced seizures. Psychoneuroendocrinology. 15:1990;165-172.
124. Young E.A., Haskett R.F., Murphy-Weinberg V., Watson S.J., Akil H. Loss of glucocorticoid fast feedback in depression. Arch. Gen. Psychiatry. 48:1991;693-699.
125. Young E.A., Lopez J.F., Murphy-Weinberg V., Watson S.J., Akil H. The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. J. Clin. Endocrinol. Metab. 83:1998;3339-3345.
126. Young E.A., Lopez J.F., Murphy-Weinberg V., Watson S.J., Akil H. Mineralocorticoid receptor function in major depression. Arch. Gen. Psychiatry. 60:2003;24-28.